PL2429317T5 - Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowego - Google Patents

Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowego

Info

Publication number
PL2429317T5
PL2429317T5 PL09776547T PL09776547T PL2429317T5 PL 2429317 T5 PL2429317 T5 PL 2429317T5 PL 09776547 T PL09776547 T PL 09776547T PL 09776547 T PL09776547 T PL 09776547T PL 2429317 T5 PL2429317 T5 PL 2429317T5
Authority
PL
Poland
Prior art keywords
omega
fatty acids
low content
phytanic acid
compositions rich
Prior art date
Application number
PL09776547T
Other languages
English (en)
Other versions
PL2429317T3 (pl
Inventor
Jose Manuel Cela Lopez
Original Assignee
Natac Pharma, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41279300&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2429317(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natac Pharma, S.L. filed Critical Natac Pharma, S.L.
Publication of PL2429317T3 publication Critical patent/PL2429317T3/pl
Publication of PL2429317T5 publication Critical patent/PL2429317T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
    • C11C1/02—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils
    • C11C1/025—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils by saponification and release of fatty acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
    • C11C1/08—Refining
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
PL09776547T 2009-04-17 2009-04-17 Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowego PL2429317T5 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09776547.3A EP2429317B2 (en) 2009-04-17 2009-04-17 Compositions rich in omega-3 fatty acids with a low content in phytanic acid
PCT/EP2009/002842 WO2010118761A1 (en) 2009-04-17 2009-04-17 Compositions rich in omega-3 fatty acids with a low content in phytanic acid

Publications (2)

Publication Number Publication Date
PL2429317T3 PL2429317T3 (pl) 2016-09-30
PL2429317T5 true PL2429317T5 (pl) 2019-09-30

Family

ID=41279300

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09776547T PL2429317T5 (pl) 2009-04-17 2009-04-17 Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowego

Country Status (14)

Country Link
US (1) US9062275B2 (pl)
EP (1) EP2429317B2 (pl)
JP (1) JP5872453B2 (pl)
KR (1) KR101759353B1 (pl)
CN (1) CN102438468B (pl)
AU (1) AU2009344374B2 (pl)
BR (1) BRPI0924012A2 (pl)
CA (1) CA2756528A1 (pl)
DK (1) DK2429317T4 (pl)
ES (1) ES2574136T5 (pl)
MX (1) MX2011010821A (pl)
PL (1) PL2429317T5 (pl)
PT (1) PT2429317T (pl)
WO (1) WO2010118761A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130245119A1 (en) * 2010-11-19 2013-09-19 Keio University Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders
CA2825022A1 (en) * 2011-01-25 2012-08-02 Nestec S.A. Methods and compositions for treating, reducing, or preventing deterioration of the visual system of animals
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
CN102747045B (zh) * 2011-04-19 2013-12-18 华中农业大学 一种猪流感h1n1亚型灭活疫苗及制备方法
CA2845868C (en) 2011-09-12 2018-11-06 Tassos GEORGIOU Use of epa and dha in treating occular disorder
EP3348262A1 (en) 2012-01-06 2018-07-18 Omthera Pharmaceuticals Inc. Methods for making dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
MY189576A (en) 2012-03-30 2022-02-17 Micelle Biopharma Inc Omega-3 fatty acid ester compositions
JP6173437B2 (ja) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
ES2621226T3 (es) * 2012-09-12 2017-07-03 Novaliq Gmbh Composiciones de alcanos semifluorados
EP3100722B1 (en) 2012-09-12 2024-03-20 Novaliq GmbH Semifluorinated alkanes for use in solubilizing meibum
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
ITMI20130354A1 (it) 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
US20160029919A1 (en) 2013-03-14 2016-02-04 UNIVERSITé LAVAL Use of electroretinography (erg) for the assessment of psychiatric disorders
EP2968147A4 (en) * 2013-03-15 2017-02-22 The Penn State Research Foundation Acid stable liposomal compositions
JP6495245B2 (ja) * 2013-04-22 2019-04-03 スマートフィッシュ・アーエス がんの治療及び／又は後治療のための魚油及びジュースを含む組成物の使用
CN105658215A (zh) * 2013-10-28 2016-06-08 雀巢产品技术援助有限公司 用于治疗具有非机械基础的吸收不良的单酰基甘油和脂溶性营养物质
EP2881456A1 (en) 2013-12-04 2015-06-10 Natac Pharma, S.L. Enzymatic method for separating phytanic acid from fats or oils containing it and recovering unaltered products free of phytanic acid
CN105828813A (zh) * 2013-12-19 2016-08-03 塔索斯·乔治奥 涉及治疗神经***损伤的疾病的ω3脂肪酸组合物
ES2889874T3 (es) * 2014-03-13 2022-01-14 Retrotope Inc Tratamiento de neuropatía óptica y reducción del estrés oxidativo inducido por esteroides con sustancias polinsaturadas estabilizadas
WO2015165507A1 (en) * 2014-04-29 2015-11-05 Georgiou Tassos Treatment of eye diseases using omega 3 fatty acids and aa/epa blood ratio
JP2016141624A (ja) * 2015-01-30 2016-08-08 有限会社ハヌマット 癌患者の予後改善剤
US10821090B2 (en) 2015-03-26 2020-11-03 Tiberio Bruzzese Purified compositions of polyunsaturated fatty acids, their preparation method and their use
WO2017038861A1 (ja) 2015-08-31 2017-03-09 日本水産株式会社 遊離多価不飽和脂肪酸含有組成物及びその製造方法
EP3385359A4 (en) * 2015-12-01 2019-07-24 Nippon Suisan Kaisha, Ltd. DOCOSAHEXAIC ACID-CONTAINING OIL AND METHOD FOR THE PRODUCTION THEREOF
CN109073648A (zh) * 2016-03-15 2018-12-21 拜尔梅里科有限公司 纤维肌痛敏感测试的组合物、设备以及方法
KR20180051737A (ko) * 2016-11-08 2018-05-17 차의과학대학교 산학협력단 대장염-관련 암 발생을 줄이는 ω-3 폴리불포화지방산 활성 성분으로 포함하는 항암 조성물
RU2652342C1 (ru) * 2017-07-13 2018-04-25 Наталья Александровна Гаврилова Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
CN108096181A (zh) * 2018-02-05 2018-06-01 西安医学院 Dha、epa在制备治疗干眼症的口服药物的应用
KR20210016746A (ko) 2019-08-05 2021-02-17 충남대학교산학협력단 오메가-3 불포화 지방산을 포함하는 항톡소포자충 조성물
EP4017484A4 (en) * 2019-08-21 2022-10-19 Burke & Boyer, Inc. MONO-UNSATURATED FATTY ACID COMPOSITION AND THEIR USE FOR THE TREATMENT OF HEPATIC STEATOSIS
CN110846346B (zh) * 2019-11-26 2021-06-22 瞿瀚鹏 富含Sn-2位DHA的微生物油脂及其制备方法和应用
KR20210018171A (ko) 2020-11-16 2021-02-17 충남대학교산학협력단 오메가-3 지방산으로의 전환을 유도하는 Caenorhabditis elegans fat-1효소를 포함하는 항톡소포자충 조성물
CN113584093B (zh) * 2021-07-30 2022-07-19 江南大学 一种高dha含量的结构脂质的制备方法及其产品
CN113995747A (zh) * 2021-10-19 2022-02-01 杭州莱樱斯生物医药科技有限公司 一种治疗脱发的产品及银杏内酯a在治疗应激诱发脱发的新用途
KR20240094157A (ko) 2022-12-13 2024-06-25 충남대학교산학협력단 노빌레틴을 유효성분으로 하는 톡소포자충 감염증의 예방 또는 치료용 조성물

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5697503A (en) * 1980-01-07 1981-08-06 Nippon Oil & Fats Co Ltd Separation of constituent component from mixed composition of plural component of org. compound
JPS57149400A (en) * 1981-03-12 1982-09-14 Kureha Chemical Ind Co Ltd Manufacture of high purity long chain highly unsaturated fatty acid ester
EP0347509A1 (en) 1988-06-21 1989-12-27 Century Laboratories Inc. A process of extraction and purification of polyunsaturated fatty acids from natural sources
US4792418A (en) * 1985-08-14 1988-12-20 Century Laboratories, Inc. Method of extraction and purification of polyunsaturated fatty acids from natural sources
IT1205043B (it) 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
US5023100A (en) 1988-05-02 1991-06-11 Kabi Vitrum Ab Fish oil
US4874629A (en) 1988-05-02 1989-10-17 Chang Stephen S Purification of fish oil
JPH0225447A (ja) * 1988-07-13 1990-01-26 Nippon Oil & Fats Co Ltd 高度不飽和脂肪酸類の製造方法
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
DK190689D0 (da) 1989-04-19 1989-04-19 Novo Industri As Omestringsproces
US5013569A (en) 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
SE9303446D0 (sv) 1993-10-20 1993-10-20 Trikonex Ab A novel urea fractionation process
CN1105205A (zh) 1994-01-11 1995-07-19 黄升 富含dha和活性钙的补脑益智营养食品及其制备方法
ES2131129T3 (es) 1994-05-09 1999-07-16 Nestle Sa Procedimiento para la preparacion de un concentrado de esteres de acidos grasos poliinsaturados.
JPH0898659A (ja) 1994-09-30 1996-04-16 Nippon Suisan Kaisha Ltd ストレスに対する改善効果を有する魚類用飼料
CN1130040A (zh) 1995-12-05 1996-09-04 杨学斌 一种含dha的健脑膨化食品
GB2350610A (en) 1999-06-01 2000-12-06 Jfs Envirohealth Ltd Preparation of pure unsaturated fatty acids
CA2311974A1 (en) 1999-06-28 2000-12-28 Nisshin Flour Milling Co., Ltd. Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
JP4530311B2 (ja) † 2000-07-13 2010-08-25 日本水産株式会社 リパーゼを用いたグリセライドの製造方法
CN1345544A (zh) * 2000-09-29 2002-04-24 国家海洋药物工程技术研究中心 海洋产物营养保健蛋的生产方法
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
CN1378846A (zh) * 2002-03-22 2002-11-13 海南加华海产生物制药有限公司 鲨鱼肝油胶丸
EP1542670B2 (en) * 2002-09-24 2023-07-05 Suntory Holdings Limited Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities in adults
US6846942B2 (en) 2003-05-20 2005-01-25 David Rubin Method for preparing pure EPA and pure DHA
CN1245169C (zh) 2004-01-29 2006-03-15 任连坤 一种提高记忆力、改善认知的纯天然复合制剂及其制备方法
CN101018862B (zh) * 2004-04-22 2013-10-09 联邦科学技术研究组织 用重组细胞合成长链多不饱和脂肪酸
KR20070090928A (ko) * 2004-11-19 2007-09-06 마텍 바이오싸이언스스 코포레이션 장쇄 다가불포화 지방산으로부터의 옥시리핀, 및 이의 제조방법 및 사용 방법
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
CN103211807A (zh) * 2005-07-08 2013-07-24 Dsmip资产公司 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
WO2007071733A2 (en) * 2005-12-21 2007-06-28 Brudy Technology, S.L. Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
US20070213298A1 (en) * 2006-02-07 2007-09-13 Universitetet I Oslo Omega 3
US8003813B2 (en) * 2006-06-27 2011-08-23 Pos Pilot Plant Corporation Process for separating saturated and unsaturated fatty acids
US7550614B2 (en) 2006-11-13 2009-06-23 Rohm And Haas Company Method for esterification of free fatty acids in triglycerides
KR100832397B1 (ko) * 2007-02-12 2008-05-26 경북대학교 산학협력단 디아실글리세롤함유 식용유지의 제조방법
CN100574772C (zh) * 2007-03-23 2009-12-30 童宥霖 一种含叶黄素的软胶囊及其制备方法
US20080268117A1 (en) 2007-04-30 2008-10-30 David Rubin Method of purifying oils containing epa and dha
WO2009020406A1 (en) * 2007-08-07 2009-02-12 Granate Seed Limited Methods of making lipid substances, lipid substances made thereby and uses thereof
CN101381298B (zh) * 2008-10-21 2011-09-07 四川省毛叶山桐子科技股份有限公司 利用毛叶山桐子油制备共轭亚油酸的方法
WO2011018096A1 (en) * 2009-08-10 2011-02-17 K.D. Pharma Bexbach Gmbh Phytanic acid fractionation process, fatty acid products and use thereof

Also Published As

Publication number Publication date
PL2429317T3 (pl) 2016-09-30
WO2010118761A1 (en) 2010-10-21
ES2574136T5 (es) 2019-08-30
CN102438468A (zh) 2012-05-02
BRPI0924012A2 (pt) 2019-09-24
EP2429317B2 (en) 2019-02-20
EP2429317A1 (en) 2012-03-21
DK2429317T4 (da) 2019-05-13
ES2574136T3 (es) 2016-06-15
JP2012523823A (ja) 2012-10-11
AU2009344374B2 (en) 2015-07-23
DK2429317T3 (en) 2016-07-18
US9062275B2 (en) 2015-06-23
KR101759353B1 (ko) 2017-07-18
MX2011010821A (es) 2012-01-20
JP5872453B2 (ja) 2016-03-01
EP2429317B1 (en) 2016-03-30
CN102438468B (zh) 2014-06-04
KR20120039521A (ko) 2012-04-25
PT2429317T (pt) 2016-07-22
US20120053242A1 (en) 2012-03-01
CA2756528A1 (en) 2010-10-21
AU2009344374A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
PL2429317T3 (pl) Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowego
IL266231A (en) Omega-3 polyunsaturated fatty acid compounds enriched in dpa in the form of a free acid phase fat
HK1198544A1 (en) Microbial oils enriched in polyunsaturated fatty acids
IL215827A0 (en) Omega-3 fatty acid enriched beverages
IL249821A0 (en) Preparations of omega 3 fatty acid esters
EP2173184A4 (en) OMEGA TYPE ENRICHED FATTY ACID COMPOSITION
IL212112A0 (en) Production of modifird fatty acids in plants
ZA201109067B (en) Acyltransferases and uses thereof in fatty acid production
EP2459189A4 (en) FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
PL2234994T3 (pl) Mieszanki estrów butylowych kwasów tłuszczowych
IL215828A0 (en) Omega-3 fatty acid enriched baked foods and bar compositions
IL214887A0 (en) Fatty acid monoglyceride compositions
ZA201302760B (en) Novel omega-3 and omega-6 fatty acid compositions and uses thereof
IL219958A0 (en) Omega-3 fatty acid enriched meat compositions
HK1170169A1 (en) Pharmaceutical composition including a dha ester to be parenterally administered dha
HK1185806A1 (zh) 含有多不飽和脂肪酸的組合物
GB0904300D0 (en) Essential fatty acid compounds
PL2550345T3 (pl) Podpałka na bazie estru kwasu tłuszczowego